Truscreen (ASX:TRU)
ASX announcement history & article coverage
Transparent by design.
Announcments by Truscreen (ASX:TRU) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notice of General Meeting/Proxy Form
Application for quotation of securities - TRU
Change in substantial holding
Becoming a substantial holder
Annual Report to Shareholders
TruScreen FY2026 audit confirms losses and going concern uncertainty amid revenue and inventory risks
Truscreen Compliance with Listing Rule 1.15.3
Rights Issue Completes Substantially Oversubscribed
TruScreen completes oversubscribed NZ$2.9m rights issue raising over NZ$4m in total capital
Rights Issue Offer to Close 17 June 2026
Milestone Markets Update
TruScreen advances global cervical cancer screening with major clinical validation and market expansion
Initial Director Disclosure Notice
Director Appointment/Retirement
Application for quotation of securities - TRU
Notification of cessation of securities - TRU
Notification of cessation of securities - TRU
Management Update
TruScreen Preliminary Final Results FY2026 Presentation
TruScreen reports 42% sales growth in FY2026, expands global footprint and advances FY2027 growth strategy
TruScreen Preliminary Final Results FY2026
TruScreen reports 42% revenue growth, NZD 2.25m loss, expands global cervical cancer screening footprint
TruScreen Appoints Uzbekistan Distributor
TruScreen Completes Oversubscribed Placement
TruScreen completes oversubscribed NZ$1.82m placement with deferred tranche and rights issue
Appendix 3B
Rights Issue Offer Document
TruScreen launches NZ$1.94M rights issue to fund global cervical cancer screening expansion
Cleansing Notice
Corporate Action Notice
TruScreen announces rights issue, placement, and bonus options to raise capital for growth and compliance
Option Extension Prospectus
TruScreen extends option expiry to July 2027 with nil-cost option issue to Australian holders
Investor Presentation
TruScreen reports 42% sales growth in FY26, advances AI cervical cancer screening tech and global expansion
Truscreen Launches Capital Raise of N$2.9 million
TruScreen launches NZ$2.9 million capital raise to fund global expansion and extends option expiry
Trading Halt
Details of Auditor Appointment/Resignation
TRU Partners with LSUTH Gates Foundation Grant Application
FY 31 March 2026 Revenue and Results Guidance Achieved
TruScreen confirms FY2026 revenue growth and loss guidance; pursues major UNITAID funding for cervical cancer screening expansion
TRU Submits Proposals for 3 Substantial Screening Programmes